Hepatocellular carcinoma (HCC) is one of the most common solid cancers in the world, with an annual incidence estimated to be at least one million new patients. Furthermore, the liver is second only to lymph nodes as a common site of metastasis from other solid cancers. Hepatocellular carcinoma is potentially curable by surgical resection, but unfortunately, only 5%-15% of newly diagnosed HCC or colorectal cancers - liver metastasis patients undergo a potentially curative resection and this because the rate presentation of the disease. So we have to find another line of treatment to these irresectable tumours. The use of RF energy to treat unresectable liver tumors is unlikely to be curative for most patients; however, a subset of patients treated with RFA may achieve long-term disease-free survival and improve the quality of life for these patients. Radiofrequency ablation (RFA) is a localized thermal treatment technique designed to produce tumor destruction by heating tumor tissue to temperatures that exceed 60°C. A typical RFA Treatment results in local tissue temperature that exceed 60˚ C up to more than 100˚ C, which produce coagulative necrosis of tumor tissue and surrounding hepatic parenchyma up to 1 cm margin of normal liver all around. RFA of liver tumors can be performed percutaneously, using laparoscopic guidance, or as part of an open surgical procedure. The choice of treatment approach is individualized in any given patient. In our study we used the laparoscopic approach in treating 55 patients. The laparoscopic approach is intended to minimize post-operative pain, reducing post-operative morbidities and speed up recovery times, while maintaining an enhanced visual field for surgeons that allows better protection of vital structures and a more accurate staging. So, LRFA is a novel, safe and effective treatment approach in treating both primary and metastatic irresectable hepatic malignancies.